Brokers Set Expectations for Unicycive Therapeutics, Inc.’s Q3 2024 Earnings (NASDAQ:UNCY)

Unicycive Therapeutics, Inc. (NASDAQ:UNCY) – HC Wainwright boosted their Q3 2024 EPS estimates for shares of Unicycive Therapeutics in a research note issued to investors on Thursday, August 15th. HC Wainwright analyst E. Arce now forecasts that the company will earn ($0.07) per share for the quarter, up from their previous estimate of ($0.17). HC Wainwright has a “Buy” rating and a $2.50 price objective on the stock. The consensus estimate for Unicycive Therapeutics’ current full-year earnings is ($0.88) per share. HC Wainwright also issued estimates for Unicycive Therapeutics’ Q4 2024 earnings at ($0.07) EPS, FY2024 earnings at ($0.12) EPS, Q1 2025 earnings at ($0.07) EPS, Q2 2025 earnings at ($0.08) EPS, Q3 2025 earnings at ($0.10) EPS, Q4 2025 earnings at ($0.08) EPS, FY2025 earnings at ($0.33) EPS, FY2026 earnings at ($0.20) EPS, FY2027 earnings at ($0.06) EPS and FY2028 earnings at $0.38 EPS.

UNCY has been the topic of several other research reports. Brookline Capital Management upgraded shares of Unicycive Therapeutics to a “strong-buy” rating in a research note on Tuesday, July 9th. Benchmark restated a “speculative buy” rating and set a $3.00 price target on shares of Unicycive Therapeutics in a research note on Friday, May 31st. Four equities research analysts have rated the stock with a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat.com, Unicycive Therapeutics currently has an average rating of “Buy” and a consensus target price of $5.13.

Unicycive Therapeutics Stock Up 3.0 %

Shares of UNCY opened at $0.31 on Monday. The company’s fifty day moving average is $0.47 and its 200-day moving average is $0.96. Unicycive Therapeutics has a 12 month low of $0.20 and a 12 month high of $1.82. The firm has a market cap of $11.62 million, a price-to-earnings ratio of -0.26 and a beta of 2.38.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. BVF Inc. IL grew its stake in Unicycive Therapeutics by 70.5% in the 1st quarter. BVF Inc. IL now owns 3,611,601 shares of the company’s stock valued at $4,984,000 after buying an additional 1,493,462 shares during the last quarter. Rosalind Advisors Inc. acquired a new position in Unicycive Therapeutics in the 1st quarter valued at $2,594,000. Finally, Virtu Financial LLC acquired a new position in Unicycive Therapeutics in the 1st quarter valued at $36,000. 40.42% of the stock is currently owned by institutional investors and hedge funds.

About Unicycive Therapeutics

Unicycive Therapeutics, Inc, a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease on dialysis; and UNI 494, which is in Phase 1 clinical trials for treatment of acute kidney injury.